Investing.com - I Mab reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
I Mab announced earnings per share of $-0.23 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.24 on revenue of $0.00.
I Mab 's are down 92% and is trading at $3.70 , still down 94.03% from its 52 week high of $61.98 set on Wednesday, December 1, 2021.
I Mab follows other major Healthcare sector earnings this month
I Mab's report follows an earnings beat by Novo Nordisk ADR on Wednesday, November 2, 2022, who reported EPS of $0.8409 on revenue of $6.04B, EPS of $0.837 on revenue of $6.04B.
AstraZeneca ADR had beat expectations on Thursday, November 10, 2022 with third quarter EPS of $1.67 on revenue of $10.98B, for EPS of $0.77 on revenue of $10.78B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar